Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.8.0.1
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2017
Stockholders Equity Tables  
Schedule of Future Amortization of Deferred Financing Costs

2017   $ 0.1  
2018   $ 0.5  
2019   $ 0.5  

Schedule of Warrants Outstanding

    September 30,     December 31,  
    2017     2016  
Issued to Investors on July 28, 2010, entitling the holders to purchase 207,000 common shares in the Company at an exercise price of $45.00 per common share up to and including July 27, 2017. At September 30, 2017, these warrants had expired and at December 31, 2016, the fair value of these warrants was not significant.     -       207,000  
                 
Issued to Investors on October 25, 2013, entitling the holders to purchase 250,000 common shares in the Company at an exercise price of $11.50 per common share up to and including April 24, 2021. In 2016, 59,450 of these warrants were exchanged for common stock, and all remaining warrant holders agreed to new warrant terms in exchange for a reduced exercise price of $6.25 per share.     163,986       163,986  
                 
Issued to Investors on November 17, 2014, entitling the holders to purchase 546,919 common shares in the Company at an exercise price of $11.55 per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms in exchange for a reduced exercise price of $6.25 per share.     546,919       546,919  
                 
Issued to an Investor on June 28, 2016, entitling the holders to purchase 295,267 common shares in the Company at an exercise price of $0.05 per common share (pre-funded) up to and including June 27, 2021, all warrants exercised on July 12, 2017.     -       295,267  
                 
Issued to an investor on August 10, 2016, entitling the holders to purchase 500,000 common shares in the Company at an exercise price of price of $0.01 per share, up to and including December 31, 2019.     500,000       500,000  
                 
      1,210,905       1,713,172  

Schedule of Share-based Compensation, Stock Options, Activity

          Weighted     Weighted  
          Average     Average  
    Options     Exercise     Grant Date  
    Outstanding     Price     Fair Value  
Beginning of the period     2,172,581     $ 6.70     $ 4.83  
Granted     31,425     $ 1.08     $ 0.81  
Exercised     --       --       --  
Forfeited     --       --       --  
Expired     (28,671 )   $ 40.35     $ 35.15  
End of the period     2,175,335     $ 6.17     $ 4.37  
                         
Options exercisable     1,762,385     $ 6.56     $ 4.70  

Schedule of Non-Vested Shares, Activity

          Weighted-        
          Average Fair     Weighted  
          Value     Average  
    Shares     Grant Date     Exercise Price  
Non-vested Shares                  
Non-vested - December 31, 2015     359,001     $ 4.55     $ 6.70  
                         
Granted     1,210,467     $ 1.71     $ 3.02  
Vested     (1,118,992 )   $ 1.81     $ 3.19  
Forfeited     -       -       -  
Non-vested - December 31, 2016     450,476     $ 3.60     $ 5.40  
Granted     31,425       0.81       1.08  
Vested     (68,951 )   $ 5.89     $ 8.82  
Forfeited     -       -       -  
Non-vested - September 30, 2017     412,950     $ 3.00     $ 4.51  

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

    Nine Months ended  
    September 30,  
    2017  
       
Average risk-free interest rate     1.85 %
Average expected life- years     6.0  
Expected volatility     88.5 %
Expected dividends     0.0